Adial regains compliance with Nasdaq’s Equity Listing requirement

Adial Pharmaceuticals (ADIL) announced that it received notice from Nasdaq on July 14, 2025 that the Company has regained compliance with Nasdaq Listing Rule 5550(b)(1), which requires listed companies to maintain stockholders’ equity of at least $2,500,000. Cary Claiborne, President and Chief Executive Officer of Adial, commented, “We’re pleased to have regained compliance with Nasdaq, a key step in reinforcing investor confidence and supporting our long-term growth strategy. This reflects our commitment to disciplined financial management as we continue advancing our pipeline and creating value for shareholders.”